gene therapy stock faces cash crunch amid launch By Investing.com
bluebird bio Inc. (NASDAQ:BLUE), a biotechnology company with a market capitalization of $81.18 million specializing in gene therapies for severe genetic diseases and cancer, finds itself at a critical juncture as it navigates the challenges of product launches and financial constraints. According to InvestingPro analysis, the company appears to be trading below its Fair Value, suggesting potential upside opportunity despite current challenges. The company’s focus on innovative treatments, particularly its lead product Lyfgenia for sickle cell disease (SCD), has garnered attention from investors and analysts alike. However, recent financial performance and operational hurdles have raised questions about the company’s near-term…
